Joseph C Presti
Overview
Explore the profile of Joseph C Presti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
376
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Presti J, Alexeeff S, Horton B, Prausnitz S, Avins A
Urol Oncol
. 2021 May;
39(11):783.e11-783.e19.
PMID: 33962850
Purpose: To prospectively validate a new prostate cancer risk calculator in a racially diverse population. Materials And Methods: We recently developed, internally validated and published the Kaiser Permanente Prostate Cancer...
2.
Harzstark A, Altschuler A, Amsden L, Alavi M, Liu L, Presti J, et al.
JCO Clin Cancer Inform
. 2021 Feb;
5:187-193.
PMID: 33571000
Purpose: In 2016, Kaiser Permanente Northern California began regionalizing testicular cancer care using population-based tumor board review. This mixed methods evaluation describes implementation outcomes and learnings. Methods: We conducted in-depth...
3.
Van Den Eeden S, Lu R, Zhang N, Quesenberry Jr C, Shan J, Han J, et al.
Eur Urol
. 2017 Oct;
73(1):129-138.
PMID: 28988753
Background: A 17-gene biopsy-based reverse transcription polymerase chain reaction assay, which provides a Genomic Prostate Score (GPS-scale 0-100), has been validated as an independent predictor of adverse pathology and biochemical...
4.
Eklund M, Nordstrom T, Aly M, Adolfsson J, Wiklund P, Brandberg Y, et al.
Eur Urol Focus
. 2017 Jul;
4(5):707-710.
PMID: 28753803
Prostate cancer screening is associated with low specificity, unnecessary biopsies, and overdiagnosis. We have previously shown that the Stockholm-3 model (S3M) can reduce biopsies compared with using prostate-specific antigen (PSA)...
5.
Keto C, Aronson W, Terris M, Presti J, Kane C, Amling C, et al.
Eur Urol
. 2012 Dec;
65(3):620-7.
PMID: 23245686
Background: A prostate-specific antigen (PSA) level <0.2 ng/ml 8 mo after starting on androgen-deprivation therapy (ADT) is correlated with better outcomes. However, not all men reach a nadir PSA level...
6.
Sonn G, Sadetsky N, Presti J, Litwin M
J Urol
. 2012 Dec;
189(1 Suppl):S59-65.
PMID: 23234635
Purpose: As the number of prostate cancer survivors increases, urologists must recognize their quality of life impairment. In the past physician ratings of patient symptoms did not correlate with patient...
7.
Ho T, Gerber L, Aronson W, Terris M, Presti J, Kane C, et al.
Eur Urol
. 2012 Aug;
62(5):910-6.
PMID: 22921964
Background: Obesity is associated with an increased risk of biochemical recurrence (BCR) after radical prostatectomy (RP). It is unclear whether this is due to technical challenges related to operating on...
8.
Keto C, Aronson W, Terris M, Presti J, Kane C, Amling C, et al.
BJU Int
. 2011 Nov;
110(4):492-8.
PMID: 22094083
Unlabelled: Study Type - Prognosis (cohort series). Level of Evidence 2a. What's known on the subject? and What does the study add? The incidence and prevalence of obesity in the...
9.
Kawachi M, Bahnson R, Barry M, Busby J, Carroll P, Carter H, et al.
J Natl Compr Canc Netw
. 2010 Feb;
8(2):240-62.
PMID: 20141680
No abstract available.
10.
Sonn G, Sadetsky N, Presti J, Litwin M
J Urol
. 2009 Sep;
182(5):2296-302.
PMID: 19758610
Purpose: As the number of prostate cancer survivors increases, urologists must recognize their quality of life impairment. In the past physician ratings of patient symptoms did not correlate with patient...